Olverembatinib in chronic myeloid leukemia

被引：2

作者：

Oziskender, Renan ^{[1
]}

Eskazan, Ahmet Emre ^{[2
]}

机构：

[1] Univ Hosp Munster, Dept Med Hematol Oncol & Pneumol A, Munster, Germany

[2] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med, Dept Internal Med, Div Hematol, Istanbul, Turkey

来源：

DRUGS OF TODAY | 2022年 / 58卷 / 11期

关键词：

Olverembatinib; Chronic myeloid; leukemia; Tyrosine kinase inhibitors; Hematologic  malignancies; T315I mutation; ABL KINASE; RESISTANCE; INHIBITOR; PONATINIB;

D O I：

10.1358/dot.2022.58.11.3441854

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The introduction of tyrosine kinase inhibitors (TKIs) rep resents a new era in the management of chronic myeloid leukemia (CML). Despite their long clinical suc-cess, point mutations emerging before or during TKI treatment remain an obstacle for several cases. T315I is one of these point mutations in the tyrosine kinase domain of BCR::ABL1. It is a major cause of resistance against first-and second-generation TKIs and there-fore lowers survival rates of a small group of patients. Olverembatinib (HQP-1351, formerly GZD-824) is a novel, orally active TKI, which acts through targeting the ATP-binding site of the BCR::ABL1 tyrosine kinase. In recent studies, olverembatinib appears to be an eff-ective and safe treatment option for CML patients har-boring T315I mutation. This article mainly focuses on the efficacy and safety data of olverembatinib along with other clinically available and potentially active drugs against T315I-mutated CML.

引用

页码：531 / 538

页数：8

共 23 条

[1]

[Anonymous], 2021, INN BIOL ASC PHARM A

[2] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].

Bower, Hannah ;

Bjorkholm, Magnus ;

Dickman, Paul W. ;

Hoglund, Martin ;

Lambert, Paul C. ;

Andersson, Therese M. -L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2851-+

[3] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[4] Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial [J].

Cortes, Jorge E. ;

Hughes, Timothy P. ;

Mauro, Michael J. ;

Hochhaus, Andreas ;

Rea, Delphine ;

Goh, Yeow Tee ;

Janssen, Jeroen ;

Steegmann, Juan Luis ;

Heinrich, Michael C. ;

Talpaz, Moshe ;

Etienne, Gabriel ;

Breccia, Massimo ;

Deininger, Michael W. ;

le Coutre, Philipp D. ;

Lang, Fabian ;

Aimone, Paola ;

Polydoros, Fotis ;

Cacciatore, Silvia ;

Stenson, Laura ;

Kim, Dong-Wook .

BLOOD, 2020, 136

[5] Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up [J].

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Rea, Delphine ;

Wetzler, Meir ;

Lipton, Jeffrey H. ;

Akard, Luke ;

Khoury, H. Jean ;

Michallet, Mauricette ;

Guerci-Bresler, Agnes ;

Chuah, Charles ;

Hellmann, Andrzej ;

Digumarti, Raghunadharao ;

Parikh, Purvish M. ;

Legros, Laurence ;

Warzocha, Krzysztof ;

Baccarani, Michele ;

Li, Elizabeth ;

Munteanu, Mihaela ;

Nicolini, Franck E. .

CANCER, 2015, 121 (10) :1637-1644

[6] Mechanisms of disease - The biology of chronic myeloid leukemia [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

O'Brien, S ;

Kurzrock, R ;

Kantarjian, HM .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172

[7] FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia [J].

Fang, Douglas D. ;

Zhu, Hengrui ;

Tang, Qiuqiong ;

Wang, Guangfeng ;

Min, Ping ;

Wang, Qixin ;

Li, Na ;

Yang, Dajun ;

Zhai, Yifan .

TRANSLATIONAL ONCOLOGY, 2022, 15 (01)

[8] European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia [J].

Hochhaus, A. ;

Baccarani, M. ;

Silver, R. T. ;

Schiffer, C. ;

Apperley, J. F. ;

Cervantes, F. ;

Clark, R. E. ;

Cortes, J. E. ;

Deininger, M. W. ;

Guilhot, F. ;

Hjorth-Hansen, H. ;

Hughes, T. P. ;

Janssen, J. J. W. M. ;

Kantarjian, H. M. ;

Kim, D. W. ;

Larson, R. A. ;

Lipton, J. H. ;

Mahon, F. X. ;

Mayer, J. ;

Nicolini, F. ;

Niederwieser, D. ;

Pane, F. ;

Radich, J. P. ;

Rea, D. ;

Richter, J. ;

Rosti, G. ;

Rousselot, P. ;

Saglio, G. ;

Saussele, S. ;

Soverini, S. ;

Steegmann, J. L. ;

Turkina, A. ;

Zaritskey, A. ;

Hehlmann, R. .

LEUKEMIA, 2020, 34 (04) :966-984

[9] Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure [J].

Hughes, T. P. ;

Mauro, M. J. ;

Cortes, J. E. ;

Minami, H. ;

Rea, D. ;

DeAngelo, D. J. ;

Breccia, M. ;

Goh, Y. -T. ;

Talpaz, M. ;

Hochhaus, A. ;

le Coutre, P. ;

Ottmann, O. ;

Heinrich, M. C. ;

Steegmann, J. L. ;

Deininger, M. W. N. ;

Janssen, J. J. W. M. ;

Mahon, F. -X. ;

Minami, Y. ;

Yeung, D. ;

Ross, D. M. ;

Tallman, M. S. ;

Park, J. H. ;

Druker, B. J. ;

Hynds, D. ;

Duan, Y. ;

Meille, C. ;

Hourcade-Potelleret, F. ;

Vanasse, K. G. ;

Lang, F. ;

Kim, D. -W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (24) :2315-2326

[10] Asciminib as a new option in the treatment of chronic myeloid leukemia [J].

Ibis, Betul ;

Tiribelli, Mario ;

Eskazan, Ahmet Emre .

FUTURE ONCOLOGY, 2021, 17 (36) :5003-5005

← 1 2 3 →